Commentary

What the National Psoriasis Foundation Means to Dermatologists and Our Patients [letter]

Cutis. 2008 September;82(3):181-183
By
Kaufman ED
Lebwohl MG
Krueger GG
Zimmerman G
Feldman SR
Author and Disclosure Information

No abstract available.
PDF Download

 

Recommended Reading

Minocycline Joins List of Lupus-Inducing Drugs
MDedge Dermatology
Bullous Pemphigoid Managed With Methotrexate
MDedge Dermatology
Autoantibodies for Bullous Pemphigoid Found in Unaffected
MDedge Dermatology
Bullous Pemphigoid and Pemphigus Vulgaris Rates Climbing in U.K.
MDedge Dermatology
Vitamin D, Estrogen May Be Key to New SLE Tx
MDedge Dermatology
Autoimmune Testing Helps Guide Urticaria Tx
MDedge Dermatology
Prevalence of Mood and Sleep Problems in Chronic Skin Diseases: A Pilot Study
MDedge Dermatology
A Single-Center, Double-Blind, Randomized Trial of the Atrophogenic Effects of Fluocinonide Cream 0.1% Versus Clobetasol Propionate Cream 0.05% in Participants With Corticosteroid-Responsive Dermatoses
MDedge Dermatology
A New Standardized Method of Evaluating Cutaneous Irritation From Topical Medications
MDedge Dermatology
Psoriasis in the Patient With Human Immunodeficiency Virus, Part 1: Review of Pathogenesis
MDedge Dermatology